We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI-Enabled Technology to Help Global Molecular Imaging Market Reach USD 11.13 Billion by 2028

By LabMedica International staff writers
Posted on 10 Sep 2019
Print article
The global molecular imaging market was estimated at USD 6.84 billion in 2018 and is projected to grow at a CAGR of 5.03% during the forecast period 2019-2028 to reach USD 11.13 billion by 2028. The market growth will be driven by significant developments in the field of multimodality and optical imaging, particularly the emergence of AI-enabled imaging technology.

These are the latest findings of Research and Markets, Inc. (Fremont CA, USA), a global B2B market intelligence and advisory firm.

Within the past few decades, the medical imaging industry has been witnessing significant technological advancements. Currently, the demand for preventive care and early diagnosis is rising due to the increasing incidence of chronic disorders. As a result, several manufacturers in the market are identifying novel methods of disease detection, including molecular imaging, which is currently the most important development.

Since the past few years, the market has been witnessing an increased demand for molecular imaging technologies such as PET, SPECT, and multimodality imaging due to rising awareness as well as increasing number of government initiatives to promote the early detection of diseases using molecular imaging. However, ongoing technological advancements such as the launch of next generation of SPECT cameras containing cadmium zinc telluride (CZT) detectors and the emergence of AI-enabled imaging technology is expected to further aid the market growth during the forecast period.

The advent of multimodality imaging technology has led to increased adoption of PET-CT, PET-MRI, SPECT-CT, and related procedures in routine practice. Currently, the oncology application-specific molecular imaging segment is expected to be the major contributor to the molecular imaging market. The launch of novel contrast agents is expanding the scope of application of molecular imaging while small molecule-based imaging agents hold a major share of the molecular imaging market.

Geographically, North America currently leads the global molecular imaging market and was valued at USD 3.89 billion in 2018. The increasing demand for minimally invasive surgeries, rising cases of chronic diseases, approval of novel radiotracers, and growing awareness of molecular imaging are driving the growth of the North American molecular imaging market. However, the Asia-Pacific molecular imaging market is expected to register the highest CAGR of 6.68% during the forecast period.

Related Links:
Research and Markets
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more